The Health of Women Monitored in the Addiction Department of the Strasbourg University Hospitals (Santé-Fem)

June 13, 2025 updated by: University Hospital, Strasbourg, France

The health of women suffering from addiction is little known and little explored in the literature. Indeed, they represent only 20% of addicted patients in general and are encountered primarily during pregnancy or complex situations involving young children.

In the Addiction Department of Strasbourg University Hospitals, the investigators have established a midwifery consultation exclusively for women of all ages.

During the treatment of the women, the investigators were able to identify the specific issues faced by women suffering from addiction and the specific care requirements for this population.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

55

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Strasbourg, France, 67091
        • Recruiting
        • Service d'addictologie - CHU de Strasbourg - France
        • Sub-Investigator:
          • Laurence LALANNE, MD, PhD
        • Contact:
        • Principal Investigator:
          • Cécile NORTH, Midwife
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Female, adult (≥ 18 years old) undergoing follow-up at the CSAPA Addictions Department of the HUS

Description

Inclusion Criteria:

  • Female, adult (≥ 18 years old)
  • Undergoing follow-up at the CSAPA Addictions Department of the HUS
  • Having met the team's midwife at least once
  • Absence of written objection in the patient's medical record regarding the reuse of her data for scientific research purposes.

Exclusion Criteria:

  • Absence of written objection in the patient's medical record regarding the reuse of her data for scientific research purposes
  • Female minor
  • Female who has not initiated follow-up with the CSAPA team
  • Women who have never had a consultation with the team's midwife

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of gynecological follow-up regardless of age compared to the general population
Time Frame: Up to 18 months
This is a retrospective study to carry out an inventory of the health status of women treated at the CSAPA (Center for Addiction Care, Support, and Prevention) of the HUS (University Hospitals of Strasbourg)
Up to 18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of Consumption of toxic drugs compared to the general population
Time Frame: Up to 18 months
This is a retrospective study to carry out an inventory of the health status of women treated at the CSAPA (Center for Addiction Care, Support, and Prevention) of the HUS (University Hospitals of Strasbourg)
Up to 18 months
Rate of sexual violence compared to the general population
Time Frame: Up to 18 months
This is a retrospective study to carry out an inventory of the health status of women treated at the CSAPA (Center for Addiction Care, Support, and Prevention) of the HUS (University Hospitals of Strasbourg)
Up to 18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 24, 2025

Primary Completion (Estimated)

September 24, 2026

Study Completion (Estimated)

September 24, 2026

Study Registration Dates

First Submitted

May 16, 2025

First Submitted That Met QC Criteria

June 13, 2025

First Posted (Actual)

June 24, 2025

Study Record Updates

Last Update Posted (Actual)

June 24, 2025

Last Update Submitted That Met QC Criteria

June 13, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 9616

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Drug Addiction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe